Cutaneous T-cell and NK-cell lymphomas: The WHO-EORTC classification and the increasing recognition of specialized tumor types

American Journal of Clinical Pathology

Volumn 127, Issue 5, 2007, Pages 670-686

  Kinney, Marsha C ^a,c   Jones, Dan ^b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

CD30; Dermatitis; Mycosis fungoides; Natural killer cell; Skin lymphoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD3 ANTIBODY; CD30 ANTIGEN; CD4 ANTIBODY; CD56 ANTIGEN; CD8 ANTIGEN;

ANTIGEN EXPRESSION; B LYMPHOCYTE; CANCER CLASSIFICATION; CANCER GROWTH; CANCER SURVIVAL; CELL ACTIVITY; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONFERENCE PAPER; CUTANEOUS T CELL LYMPHOMA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LYMPHOCYTIC INFILTRATION; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MYCOSIS FUNGOIDES; NATURAL KILLER T CELL; PATHOGENESIS; PRIORITY JOURNAL; SKIN LYMPHOMA; TUMOR BIOPSY; WORINGER KOLOPP DISEASE; CLASSIFICATION; NATURAL KILLER CELL; PATHOLOGY; REVIEW; SKIN TUMOR; WORLD HEALTH ORGANIZATION;

ANTIGENS, CD30; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOPROLIFERATIVE DISORDERS; MYCOSIS FUNGOIDES; SKIN NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 34249697023     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/MTTM86UT1XFQL7RV     Document Type: Conference Paper

References (164)

1. Bouaziz JD, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Relative frequency and survival of patients with primary cutaneous lymphomas: data from a single-centre study of 203 patients. Br J Dermatol. 2006;154:1206-1207.
2. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.
3. LeBoit PE, Burg G, Weedon D, et al, eds. Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006. World Health Organization Classification of Tumours.
4. Slater DN. The new World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br J Dermatol. 2005;153:874-880.
5. Jaffe ES, Harris NL, Stein H, et al, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001. World Health Organization Classification of Tumours.
6. Burg G, Kempf W, Smoller B, et al. Mycosis fungoides. In: LeBoit P, Burg G, Weedon D, et al, eds. Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006:169-174. World Health Organization Classification of Tumours.
7. Massone C, Kodama K, Kerl H, et al. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol. 2005;29:550-560.
8. Kodama K, Fink-Puches R, Massone C, et al. Papular mycosis fungoides: a new clinical variant of early mycosis fungoides. J Am Acad Dermatol. 2005;52:694-698.
9. Kazakov DV, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol. 2004;18:397-415.
10. Smoller BR, Bishop K, Glusac E, et al. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol. 1995;19:1423-1430.
11. Naraghi ZS, Seirafi H, Valikhani M, et al. Assessment of histologic criteria in the diagnosis of mycosis fungoides. Int J Dermatol. 2003;42:45-52.
12. Santucci M, Biggeri A, Feller AC, et al, for the European Organization for Research and Treatment of Cancer. Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC Cutaneous Lymphoma Study Group investigation. Am J Surg Pathol. 2000;24:40-50.
13. Lu D, Patel KA, Duvic M, et al. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J Cutan Pathol. 2002;29:465-472.
14. Wallace ML, Smoller BR. Immunohistochemistry in diagnostic dermatopathology. J Am Acad Dermatol. 1996;34(2 pt 1):163-186.
15. Chen M, Deng A, Crowson AN, et al. Assessment of T-cell clonality via T-cell receptor-gamma rearrangements in cutaneous T-cell-dominant infiltrates using polymerase chain reaction and single-stranded DNA conformational polymorphism assay. Appl Immunohistochem Mol Morphol. 2004;12:373-379.
16. Wolff-Sneedorff A, Thomsen K, Secher L, et al. Gene rearrangement in positive patch tests. Exp Dermatol. 1995;4:322-326.
17. Vega F, Luthra R, Medeiros LJ, et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood. 2002;100:3369-3373.
18. Tokura Y, Jaffe ES, Sander CA. Cutaneous adult T-cell leukaemia/lymphoma. In: LeBoit P, Burg G, Weedon D, et al, eds. Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006:189-190. World Health Organization Classification of Tumours.
19. Johno M, Ohishi M, Kojo Y, et al. Cutaneous Manifestations of Adult T-Cell Leukemia/Lymphoma. London, England: Taylor & Francis; Gann Monograph on Cancer Research. Vol 39. 1992:33-41.
20. Leong AS, Sage RE, Kinnear GC, et al. Preferential epidermotropism in adult T-cell leukemia-lymphoma. Am J Surg Pathol. 1980;4:421-430.
21. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002;138:191-198.
22. Pereyo NG, Requena L, Galloway J, et al. Follicular mycosis fungoides: a clinicohistopathologic study. J Am Acad Dermatol. 1997;36:563-568.
23. Kato N, Yasukawa K, Kimura K, et al. Anaplastic large-cell lymphoma associated with acquired ichthyosis. J Am Acad Dermatol. 2000;42:914-920.
24. Hodak E, Amitay I, Feinmesser M, et al. Ichthyosiform mycosis fungoides: an atypical variant of cutaneous T-cell lymphoma. J Am Acad Dermatol. 2004;50:368-374.
25. Gilliam AC, Lessin SR, Wilson DM, et al. Folliculotropic mycosis fungoides with large-cell transformation presenting as dissecting cellulitis of the scalp. J Cutan Pathol. 1997;24:169-175.
26. Cerroni L, Fink-Puches R, El-Shabrawi-Caelen L, et al. Solitary skin lesions with histopathologic features of early mycosis fungoides. Am J Dermatopathol. 1999;21:518-524.
27. Heald PW, Glusac EJ. Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant. J Am Acad Dermatol. 2000;42:283-285.
28. Hodak E, Phenig E, Amichai B, et al. Unilesional mycosis fungoides: a study of seven cases. Dermatology. 2000;201:300-306.
29. Oliver GF, Winkelmann RK. Unilesional mycosis fungoides: a distinct entity. J Am Acad Dermatol. 1989;20:63-70.
30. Steffen C. Ketron-Goodman disease, Woringer-Kolopp disease, and pagetoid reticulosis. Am J Dermatopathol. 2005;27:68-85.
31. Woringer MF, Kolopp P. Lesion erythemato-squameuse polycyclique de l'avant-bras evoluant depuis 6 ans chez un garconnet de 13 ans. Ann Dermatol Syphilol. 1939;10:945-958.
32. Braun-Falco O, Marghescu S, Wolff HH. Pagetoide reticulosis: Woringer-Kolopp's disease [in German]. Hautarzt. 1973;24:11-21.
33. Haghighi B, Smoller BR, LeBoit PE, et al. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol. 2000;13:502-510.
34. Harman M, Akdeniz S, Arslan A, et al. Mycosis fungoides with involvement of the oral cavity. J Eur Acad Dermatol Venereol. 1998;10:253-256.
35. Sirois DA, Miller AS, Harwick RD, et al. Oral manifestations of cutaneous T-cell lymphoma: a report of eight cases. Oral Surg Oral Med Oral Pathol. 1993;75:700-705.
36. de la Fuente EG, Rodriguez-Peralto JL, Ortiz PL, et al. Oral involvement in mycosis fungoides: report of two cases and a literature review. Acta Derm Venereol. 2000;80:299-301.
37. Clarijs M, Poot F, Laka A, et al. Granulomatous slack skin: treatment with extensive surgery and review of the literature. Dermatology. 2003;206:393-397.
38. Camacho FM, Burg G, Moreno JC, et al. Granulomatous slack skin in childhood. Pediatr Dermatol. 1997;14:204-208.
39. van Haselen CW, Toonstra J, van der Putte SJ, et al. Granulomatous slack skin: report of three patients with an updated review of the literature. Dermatology. 1998;196:382-391.
40. Tsang WY, Chan JK, Loo KT, et al. Granulomatous slack skin. Histopathology. 1994;25:49-55.
41. Wada K, Maesawa C, Satoh T, et al. A case of primary cutaneous CD30+ T-cell lymphoproliferative disorder with features of granulomatous slack skin disease. Br J Dermatol. 2002;147:998-1002.
42. Balus L, Manente L, Remotti D, et al. Granulomatous slack skin: report of a case and review of the literature. Am J Dermatopathol. 1996;18:199-206.
43. von den Driesch P, Mielke V, Simon M Jr, et al. "Granulomatous slack skin": cutaneous elastolytic lymphoma [in German]. Hautarzt. 1994;45:861-865.
44. Noto G, Pravata G, Miceli S, et al. Granulomatous slack skin: report of a case associated with Hodgkin's disease and a review of the literature. Br J Dermatol. 1994;131:275-279.
45. Vergier B, de Muret A, Beylot-Barry M, et al, for the French Study Group of Cutaneous Lymphomas. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. Blood. 2000;95:2212-2218.
46. Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma: a clinicopathologic and immunologic study. Am J Pathol. 1988;132:265-277.
47. Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis. Blood. 1998;92:1150-1159.
48. Lu D, Duvic M, Medeiros LJ, et al. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol. 2001;115:413-421.
49. Vermeer MH, Geelen FA, Kummer JA, et al. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. Am J Pathol. 1999;154:1203-1210.
50. Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J Cutan Pathol. 2006;33(suppl 1):58-70.
51. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95:3653-3661.
52. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol. 1992;126:596-602.
53. Wang HH, Myers T, Lach LJ, et al. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer. 1999;86:1240-1245.
54. Drews R, Samel A, Kadin ME. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg. 2000;19:109-117.
55. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
56. Kadin ME, Sako D, Berliner N, et al. Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood. 1986;68:1042-1049.
57. Beljaards RC, Meijer CJ, Scheffer E, et al. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin: a clinicopathologic and immunohistochemical study in 20 patients. Am J Pathol. 1989;135:1169-1178.
58. Beljaards RC, Kaudewitz P, Berti E, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis: a European multicenter study of 47 patients. Cancer. 1993;71:2097-2104.
59. Paulli M, Berti E, Rosso R, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin: clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group. J Clin Oncol. 1995;13:1343-1354.
60. Kumar S, Pittaluga S, Raffeld M, et al. Primary cutaneous CD30-positive anaplastic large cell lymphoma in childhood: report of 4 cases and review of the literature. Pediatr Dev Pathol. 2005;8:52-60.
61. Fink-Puches R, Chott A, Ardigo M, et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol. 2004;21:525-533.
62. Vergier B, Beylot-Barry M, Pulford K, et al. Statistical evaluation of diagnostic and prognostic features of CD30+ cutaneous lymphoproliferative disorders: a clinicopathologic study of 65 cases. Am J Surg Pathol. 1998;22:1192-1202.
63. Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: a retrospective cohort study of 35 cases. Arch Dermatol. 2004;140:306-312.
64. Sioutos N, Kadin ME. Perivascular Ki-1 + lesions. Int J Hematol. 1992;55:275-279.
65. Macgrogan G, Vergier B, Dubus P, et al. CD30-positive cutaneous large cell lymphomas: a comparative study of clinicopathologic and molecular features of 16 cases. Am J Clin Pathol. 1996;105:440-450.
66. Mann KP, Hall B, Kamino H, et al. Neutrophil-rich, Ki-1-positive anaplastic large-cell malignant lymphoma. Am J Surg Pathol. 1995;19:407-416.
67. Jhala DN, Medeiros LJ, Lopez-Terrada D, et al. Neutrophilrich anaplastic large cell lymphoma of T-cell lineage: a report of two cases arising in HIV-positive patients. Am J Clin Pathol. 2000;114:478-482.
68. Burg G, Kempf W, Kazakov DV, et al. Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophilrich CD30+ anaplastic large-cell lymphoma: clinicopathological study of four cases and review of the literature. Br J Dermatol. 2003;148:580-586.
69. Lin JH, Lee JY. Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia. J Cutan Pathol. 2004;31:458-461.
70. El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch Dermatol. 2004;140:441-447.
71. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28:973-980.
72. ten Berge RL, Oudejans JJ, Ossenkoppele GJ, et al. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol. 2000;53:445-450.
73. DeCoteau JF, Butmarc JR, Kinney MC, et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood. 1996;87:3437-3441.
74. Sasaki K, Sugaya M, Fujita H, et al. A case of primary cutaneous anaplastic large cell lymphoma with variant anaplastic lymphoma kinase translocation. Br J Dermatol. 2004;150:1202-1207.
75. Bonzheim I, Geissinger E, Roth S, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood. 2004;104:3358-3360.
76. Admirand JH, Rassidakis GZ, Abruzzo LV, et al. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol. 2004;17:954-961.
77. Felgar RE, Salhany KE, Macon WR, et al. The expression of TIA-1+ cytolytic-type granules and other cytolytic lymphocyte-associated markers in CD30+ anaplastic large cell lymphomas (ALCL): correlation with morphology, immunophenotype, ultrastructure, and clinical features. Hum Pathol. 1999;30:228-236.
78. Boulland ML, Wechsler J, Bagot M, et al. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology. 2000;36:136-144.
79. Nascimento AF, Pinkus JL, Pinkus GS. Clusterin, a marker for anaplastic large cell lymphoma: immunohistochemical profile in hematopoietic and nonhematopoietic malignant neoplasms. Am J Clin Pathol. 2004;121:709-717.
80. Saffer H, Wahed A, Rassidakis GZ, et al. Clusterin expression in malignant lymphomas: a survey of 266 cases. Mod Pathol. 2002;15:1221-1226.
81. Lae ME, Ahmed I, Macon WR. Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol. 2002;118:773-779.
82. Suzuki R, Kagami Y, Takeuchi K, et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. Blood. 2000;96:2993-3000.
83. Bekkenk MW, Jansen PM, Meijer CJ, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004;15:1097-1108.
84. Magro CM, Crowson AN, Morrison C, et al. CD8+ lymphomatoid papulosis and its differential diagnosis. Am J Clin Pathol. 2006;125:490-501.
85. de Bruin PC, Beljaards RC, van Heerde P, et al. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. Histopathology. 1993;23:127-135.
86. Kadin ME, Naeem H, Kieffer D, et al. Differential expression of cutaneous lymphocyte antigen in lymphomatoid papulosis and lymphomas is a potential marker for diagnosis and tumor progression [abstract]. J Invest Dermatol. 2004;122:A30.
87. Kempf W, Levi E, Kamarashev J, et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol. 2002;29:295-300.
88. Kadin ME, Levi E, Kempf W. Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. Ann N Y Acad Sci. 2001;941:59-68.
89. Basarab T, Fraser-Andrews EA, Orchard G, et al. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol. 1998;139:630-638.
90. Steinhoff M, Hummel M, Anagnostopoulos I, et al. Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. Blood. 2002;100:578-584.
91. Kadin ME, Vonderheid EC, Sako D, et al. Clonal composition of T cells in lymphomatoid papulosis. Am J Pathol. 1987;126:13-17.
92. Chott A, Vonderheid EC, Olbricht S, et al. The dominant T cell clone is present in multiple regressing skin lesions and associated T cell lymphomas of patients with lymphomatoid papulosis. J Invest Dermatol. 1996;106:696-700.
93. Gellrich S, Wernicke M, Wilks A, et al. The cell infiltrate in lymphomatoid papulosis comprises a mixture of polyclonal large atypical cells (CD30-positive) and smaller monoclonal T cells (CD30-negative). J Invest Dermatol. 2004;122:859-861.
94. Coyne JD, Banerjee SS, Bromley M, et al. Post-transplant T-cell lymphoproliferative disorder/T-cell lymphoma: a report of three cases of T-anaplastic large-cell lymphoma with cutaneous presentation and a review of the literature. Histopathology. 2004;44:387-393.
95. Kaplan MA, Jacobson JO, Ferry JA, et al. T-cell lymphoma of the vulva in a renal allograft recipient with associated hemophagocytosis. Am J Surg Pathol. 1993;17:842-849.
96. Pitman SD, Rowsell EH, Cao JD, et al. Anaplastic large cell lymphoma associated with Epstein-Barr virus following cardiac transplant. Am J Surg Pathol. 2004;28:410-415.
97. Yurtsever H, Kempf W, Laeng RH. Posttransplant CD30+ anaplastic large cell lymphoma with skin and lymph node involvement. Dermatology. 2003;207:107-110.
98. Kim HK, Jin SY, Lee NS, et al. Posttransplant primary cutaneous Ki-1 (CD30)+/CD56+ anaplastic large cell lymphoma. Arch Pathol Lab Med. 2004;128:e96-e99.
99. Kohler S, Iwatsuki K, Jaffe ES, et al. Extranodal NK/T-cell lymphoma, nasal-type. In: LeBoit P, Burg G, Weedon D, et al, eds. Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006:191-192. World Health Organization Classification of Tumours.
100. Mraz-Gernhard S, Natkunam Y, Hoppe RT, et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol. 2001;19:2179-2188.
101. Yamashita Y, Tsuzuki T, Nakayama A, et al. A case of natural killer/T cell lymphoma of the subcutis resembling subcutaneous panniculitis-like T cell lymphoma. Pathol Int. 1999;49:241-246.
102. Chang SE, Huh J, Choi JH, et al. Clinicopathological features of CD56+ nasal-type T/natural killer cell lymphomas with lobular panniculitis. Br J Dermatol. 2000;142:924-930.
103. Natkunam Y, Smoller BR, Zehnder JL, et al. Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am J Surg Pathol. 1999;23:571-581.
104. Kobashi Y, Nakamura S, Sasajima Y, et al. Inconsistent association of Epstein-Barr virus with CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Histopathology. 1996;28:111-120.
105. Natkunam Y, Warnke RA, Haghighi B, et al. Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. J Cutan Pathol. 2000;27:392-399.
106. Herling M, Rassidakis GZ, Jones D, et al. Absence of Epstein-Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to World Health Organization criteria. Hum Pathol. 2004;35:455-459.
107. Herbst H, Sander C, Tronnier M, et al. Absence of anaplastic lymphoma kinase (ALK) and Epstein-Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Br J Dermatol. 1997;137:680-686.
108. Agarwal S, Remanathan U, Naresh KN. Epstein-Barr virus association and ALK gene expression in anaplastic large-cell lymphoma. Hum Pathol. 2002;33:146-152.
109. Soler J, Bordes R, Ortuno F, et al. Aggressive natural killer cell leukaemia/lymphoma in two patients with lethal midline granuloma. Br J Haematol. 1994;86:659-662.
110. Chang SE, Lee SY, Choi JH, et al. Cutaneous dissemination of nasal NK/T-cell lymphoma with bone marrow, liver and lung involvement. Clin Exp Dermatol. 2002;27:120-122.
111. Imamura N, Kusunoki Y, Kawa-Ha K, et al. Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature: possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol. 1990;75:49-59.
112. Radonich MA, Lazova R, Bolognia J. Cutaneous natural killer/T-cell lymphoma. J Am Acad Dermatol. 2002;46:451-456.
113. Nava VE, Jaffe ES. The pathology of NK-cell lymphomas and leukemias. Adv Anat Pathol. 2005;12:27-34.
114. Oshimi K, Kawa K, Nakamura S, et al. NK-cell neoplasms in Japan. Hematology. 2005;10:237-245.
115. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, et al. Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol. 2002;10:7-14.
116. Chen HH, Hsiao CH, Chiu HC. Hydroa vacciniforme - like primary cutaneous CD8-positive T-cell lymphoma. Br J Dermatol. 2002;147:587-591.
117. Magana M, Sangueza P, Gil-Beristain J, et al. Angiocentric cutaneous T-cell lymphoma of childhood (hydroa-like lymphoma): a distinctive type of cutaneous T-cell lymphoma. J Am Acad Dermatol. 1998;38:574-579.
118. Gentile TC, Uner AH, Hutchison RE, et al. CD3+, CD56+ aggressive variant of large granular lymphocyte leukemia. Blood. 1994;84:2315-2321.
119. Gonzalez CL, Medeiros LJ, Braziel RM, et al. T-cell lymphoma involving subcutaneous tissue: a clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol. 1991;15:17-27.
120. Jaffe ES, Burg G. Subcutaneous panniculitis-like T-cell lymphoma. In: LeBoit P, Burg G, Weedon D, et al, eds. Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006:182-183. World Health Organization Classification of Tumours.
121. Wick MR, Patterson JW. Cytophagic histiocytic panniculitis: a critical reappraisal. Arch Dermatol. 2000;136:922-924.
122. Krenacs L, Smyth MJ, Bagdi E, et al. The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. Blood. 2003;101:3590-3593.
123. Sen F, Rassidakis GZ, Jones D, et al. Apoptosis and proliferation in subcutaneous panniculitis-like T-cell lymphoma. Mod Pathol. 2002;15:625-631.
124. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998;22:881-893.
125. Lozzi GP, Massone C, Citarella L, et al. Rimming of adipocytes by neoplastic lymphocytes: a histopathologic feature not restricted to subcutaneous T-cell lymphoma. Am J Dermatopathol. 2006;28:9-12.
126. Massone C, Kodama K, Salmhofer W, et al. Lupus erythematosus panniculitis (lupus profundus): clinical, histopathological, and molecular analysis of nine cases. J Cutan Pathol. 2005;32:396-404.
127. Arnulf B, Copie-Bergman C, Delfau-Larue M-H, et al. Nonhepatosplenic γδ T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood. 1998;91:1723-1731.
128. Toro JR, Beaty M, Sorbara L, et al. γδ T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol. 2000;136:1024-1032.
129. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101:3407-3412.
130. Munn SE, McGregor JM, Jones A, et al. Clinical and pathological heterogeneity in cutaneous gamma-delta T-cell lymphoma: a report of three cases and a review of the literature. Br J Dermatol. 1996;135:976-981.
131. de Wolf-Peeters C, Achten R. γδ T-cell lymphomas: a homogeneous entity? Histopathology. 2000;36:294-305.
132. Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004;28:719-735.
133. Ralfkiaer E, Willemze R, Meijer CJLM, et al. Primary cutaneous peripheral T-cell lymphoma, unspecified. In: LeBoit P, Burg G, Weedon D, et al, eds. Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006:184-188. World Health Organization Classification of Tumours.
134. Wang H, Medeiros LJ, Jones D. Subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma. 2002;3:181-183.
135. Avinoach I, Halevy S, Argov S, et al. gamma/delta T-cell lymphoma involving the subcutaneous tissue and associated with a hemophagocytic syndrome. Am J Dermatopathol. 1994;16:426-433.
136. Ahmad E, Kingma DW, Jaffe ES, et al. Flow cytometric immunophenotypic profiles of mature gamma delta T-cell malignancies involving peripheral blood and bone marrow. Cytometry B Clin Cytom. 2005;67:6-12.
137. Berti E, Cerri A, Cavicchini S, et al. Primary cutaneous gamma/delta T-cell lymphoma presenting as disseminated pagetoid reticulosis. J Invest Dermatol. 1991;96:718-723.
138. Jones D, Vega F, Sarris AH, et al. CD4-CD8-"double-negative" cutaneous T-cell lymphomas share common histologic features and an aggressive clinical course. Am J Surg Pathol. 2002;26:225-231.
139. Kanavaros P, Lescs MC, Briere J, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood. 1993;81:2688-2695.
140. Belhadj K, Reyes F, Farcet J-P, et al. Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102:4261-4269.
141. Kagami Y, Nakamura S, Suzuki R, et al. A nodal gamma/delta T-cell lymphoma with an association of Epstein-Barr virus. Am J Surg Pathol. 1997;21:729-736.
142. Ohshima K, Haraoka S, Harada N, et al. Hepatosplenic γδ T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules. Histopathology. 2000;36:127-135.
143. Agnarsson BA, Vonderheid EC, Kadin ME. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol. 1990;22:569-577.
144. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483-492.
145. El-Shabrawi-Caelen L, Cerroni L, Medeiros LJ, et al. Hypopigmented mycosis fungoides: frequent expression of a CD8+ T-cell phenotype. Am J Surg Pathol. 2002;26:450-457.
146. Smolle J, Torne R, Soyer HP, et al. Immunohistochemical classification of cutaneous pseudolymphomas: delineation of distinct patterns. J Cutan Pathol. 1990;17:149-159.
147. Cerroni L, Goteri G. Differential diagnosis between cutaneous lymphoma and pseudolymphoma. Anal Quant Cytol Histol. 2003;25:191-198.
148. Rijlaarsdam JU, Scheffer E, Meijer CJ, et al. Cutaneous pseudo-T-cell lymphomas: a clinicopathologic study of 20 patients. Cancer. 1992;69:717-724.
149. Magro CM, Crowson AN. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis. Hum Pathol. 1996;27:125-132.
150. Magro CM, Crowson AN, Kovatich AJ, et al. Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. Hum Pathol. 2003;34:119-129.
151. Cepeda LT, Pieretti M, Chapman SF, et al. CD30-positive atypical lymphoid cells in common non-neoplastic cutaneous infiltrates rich in neutrophils and eosinophils. Am J Surg Pathol. 2003;27:912-918.
152. Rose C, Starostik P, Brocker EB. Infection with parapoxvirus induces CD30-positive cutaneous infiltrates in humans. J Cutan Pathol. 1999;26:520-522.
153. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol. 2006;142:198-202.
154. Magro CM, Crowson AN, Schapiro BL. The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J Cutan Pathol. 1998;25:72-78.
155. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol. 2004;31:1955-1958.
156. Devos SA, Van Den Bossche N, De Vos M, et al. Adverse skin reactions to anti - TNF-alpha monoclonal antibody therapy. Dermatology. 2003;206:388-390.
157. Srivastava M, Rencic A, Nousari HC. A rapidly expanding ulcer: myelodysplastic syndrome - associated (paraneoplastic) pyoderma gangrenosum. Arch Dermatol. 2003;139:531-536.
158. Srivastava MD, Alexander F, Tuthill RJ. Immunology of cutaneous vasculitis associated with both etanercept and infliximab. Scand J Immunol. 2005;61:329-336.
159. Adams AE, Zwicker J, Curiel C, et al. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J Am Acad Dermatol. 2004;51:660-662.
160. Mahe E, Descamps V, Grossin M, et al. CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximab. Br J Dermatol. 2003;149:170-173.
161. Berthelot C, Cather J, Jones D, et al. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma. 2006;6:329-332.
162. Magro CM, Crowson AN. The spectrum of cutaneous lesions in rheumatoid arthritis: a clinical and pathological study of 43 patients. J Cutan Pathol. 2003;30:1-10.
163. Long D, Thiboutot DM, Majeski JT, et al. Interstitial granulomatous dermatitis with arthritis. J Am Acad Dermatol. 1996;34:957-961.
164. Monterroso V, Bujan W, Jaramillo O, et al. Subcutaneous tissue involvement by T-cell lymphoma: a report of 2 cases. Arch Dermatol. 1996;132:1345-1350.